NeuExcell Therapeutics Inc.

When asked about the rationale behind choosing the central nervous system (CNS) area as her biotech devotion, Joan (Huaqiong) Shen, CEO of Chinese bioventure NeuShen Therapeutics, said that it has pot

Shares of Beijing Luzhu Biopharmaceutical Co Ltd (Luzhu Biotech) were listed on the Hong Kong Stock Exchange on 8 May, making the Chinese developer of vaccines and monoclonal and bispecific antibodi

After leading a Nasdaq-listed Chinese biotech, I-Mab Biopharma Co., Ltd , as CEO for years, Joan Shen has started and is CEO of her own new bioventure, NeuShen Therapeutics, which is focusing on cent

Coming off clinical development setbacks, including a failed effort to expand Ingrezza’s label into pediatric Tourette’s syndrome, Neurocrine Biosciences, Inc. reported positive R&D news to its share